Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer - Mavroudis, D; Papakotoulas, P; Ardavanis, A (Ann Oncol, 2010)
et al.